Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis: Rationale and clinical results

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 1, 1997, Pages 77-81

  Crowther, Mark ^a   Hirsh, Jack ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Deep venous thrombosis; heparin; home treatment; low molecular weight heparins; oral anticoagulants

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; CONFERENCE PAPER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HOME CARE; HUMAN; OUTPATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; VEIN THROMBOSIS;

EID: 0030990740     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996073     Document Type: Conference Paper

References (32)

1. Hull R, T Delmore, E Genton, J Hirsh, M Gent, D Sackett, D McLoughlin, P Armstrong: Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 301:855-858, 1979.
2. Hirsh J: The optimal duration of anticoagulant therapy for venous thrombosis. N Engl J Med 332:1710-1711, 1995.
3. Hull RD, GE Raskob, D Rosenbloom, AA Panju, P Brill-Edwards, JS Ginsberg, J Hirsh, GJ Martin, D Green: Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 322:1260-1264, 1990.
4. Hirsh J: Heparin. N Engl J Med 324:1565-1574, 1991.
5. Hull RD, GE Raskob, J Hirsh, RM Jay, JR Leclerc, WHR Geerts, DL Sackett, C Anderson, L Harrison: Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315:1109-1114, 1986.
6. Hirsh J, JE Dalen, D Deykin, L Poller, HI Bussey: Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 108:231S-246S, 1995.
7. Hull R, J Hirsh, R Jay, C Carter, C England, M Gent, AGM Turpie, P Dodd, M Thomas, G Raskob: Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 307:1676-1681, 1982.
8. Landefeld CS, MW Rosenblatt, L Goldman: Bleeding in outpatients treated with warfarin: Relation to the prothrombin time and important remediable lesions. AmJ Med 87:153-159, 1989.
9. Landefeld CS, L Goldman: Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87:144-152, 1989.
10. Koopman MMW, P Prandoni, F Piovella, PA Ockelford, DP Brandjes, J Van der Meer, AS Gallus, G Simmoneau, CH Chesterman, MH Prins: Treatment of patients with proximalvein thrombosis with intravenous unfractionated heparin in nospital compared with subcutaneous low-molecular-weight heparin out of hospital or with early discharge. N Engl J Med 334:682-687, 1996.
11. Levine M, M Gent, J Hirsh, J Leclerc, D Anderson, J Weitz, JS Ginsberg, AG Turpie, C Demers, M Kovacs: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334:677-681, 1996.
12. Monreal M, E Lafoz, A Olive, L del Rio, C Vedia: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemostas 71:7-11, 1994.
13. Pini M, S Aiello, C Manotti, C Pattacini, R Quintavalla, TT Poli, AG Dettori: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemostas 72:191-197, 1994.
14. Kakkar VV: Dalteparin prevention of recurrent DVT - A study versus warfarin. Haemostasis 24(Suppl 1):45 (Abstr), 1994.
15. Hirsh J, MN Levine: Low molecular weight heparin. Blood 79:1-17, 1992.
16. Frydman AM, L Bara, Y Le Roux, M Woler, F Chauliac, MM Samama: The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 28: 609-618, 1988.
17. Briant L, C Caranobe, S Saivin, P Sie, B Bayrou, G Hoin, B Boneu: Unfractionated heparin and CY 216: Pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemostas 61:348-353, 1989.
18. Bratt G, E Tornebohm, L Widlund, D Lockner: Low molecular weight heparin (KABI 2165, Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 42:613-620, 1986.
19. Matzsch T, D Bergqvist, U Hedner, P Østergaard: Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemostas 57:97-101, 1987.
20. Handeland GF, U Abildgaard, HA Holm, KE Arnesen: Dose adjusted heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 39:107-112, 1990.
21. Boneu B, MR Buchanan, C Caranobe, AM Gabaig, D Dupouy, P Sie, J Hirsh: The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits. Thromb Res 46:845-853, 1987.
22. Young E, P Wells, S Holloway, J Weitz, J Hirsh: Ex-vivo and invitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemostas 71:300-304, 1994.
23. Young E, B Cosmi, J Weitz, J Hirsh: Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins. Thromb Haemostas 70:625-630, 1993.
24. Warkentin TE, MN Levine, J Hirsh, P Horsewood, RS Roberts, MK Gent: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335, 1995.
25. Murray WJ, VS Lindo, VV Kakkar, E Melissari: Long-term administration of heparin and heparin fractions and osteoporosis in experimental animals. Blood Coag Fibrinolysis 6:113-118, 1995.
26. Carter CJ, JG Kelton, J Hirsh, A Cerskus, AV Santos, M Gent: The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 59:1239-1245, 1982.
27. Esquivel CO, D Bergqvist, CG Bjorck, B Nilsson: Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo. Thromb Res 28:389-399, 1982.
28. Cade JF, MR Buchanan, B Boneu, P Ockelford, CJ Cater, ALH Cerskus: A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res 35:613-625, 1984.
29. Holmer E, C Mattsson, S Nilsson: Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 25:475-485, 1982.
30. Andriuoli G, R Mastacchi, M Barbanti, M Sarret: Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats. Haemostasis 15:324-330, 1985.
31. Bergqvist D, B Nilsson, U Hedner, PC Pedersen, PB Østergaard: The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res 38: 589-601, 1985.
32. Lensing AW, MH Prins, BL Davidson, J Hirsh: Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 155:601-607, 1995.